The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism

Krysiak, Robert; Gilowski, Wojciech

doi:10.1016/j.pharep.2015.08.009

Cited by 10 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results were consistent with some previous studies (18)(19)(20)(21)23). A cross-sectional study conducted by Chao (18) indicated a significant negative correlation between SUA and testosterone levels in T2DM males.…”

Section: Discussionsupporting

confidence: 93%

“…Elevated SUA levels are associated with metabolic syndrome and insulin resistance, both of which increase the risk of low testosterone, so there might be a negative correlation between SUA and testosterone. Some studies have proved SUA is a risk factor for gonadal dysfunction (18), indicating a negative correlation between SUA and testosterone levels (19)(20)(21)(22)(23), which is consistent with our results. However, other studies have come to a different conclusion (24)(25)(26)(27).…”

Section: Introductionsupporting

confidence: 93%

“…In another prospective cohort of 31 men with LOH, 16 participants received intramuscular testosterone enanthate (100 mg weekly). After 4 months of therapy, increased testosterone levels and decreased UA levels were identified in patients treated with testosterone compared with the control group (23). However, there is also some controversial evidence (24,26,27,50).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Exploration of the association between serum uric acid and testosterone in adult males: NHANES 2011–2016

Han¹,

Zhang²,

Cao³

et al. 2021

Transl Androl Urol

View full text Add to dashboard Cite

Background: Previous studies have suggested that the possible relationship between serum uric acid (SUA) and testosterone. However, the results of previous studies are controversial and there is limited evidence examining the relationship between SUA and testosterone in a general US population of men. The objective of this study is to explore the correlation of SUA and testosterone among adult males from the US.Methods: Data from the National Health and Nutrition Examination Survey 2011-2016 were used, including a total of 7,796 male participants aged 18 years or older and excluding those lacking serum testosterone and uric acid data. Clinical characteristics of the participants among different SUA groups and testosterone groups are compared. Univariate and multivariate linear regression analyses were applied to evaluate the association between SUA and testosterone. Results:We found an inverse association between SUA and testosterone after fully adjusted the potential confounding factors in general US adult males. In the multivariate linear regression analysis, we found that increasing age (estimate testosterone percent difference: −0.20% per year, P<0.01), uric acid (estimate testosterone percent difference: −4.40% per md/dL, P<0.01) and BMI (estimate testosterone percent difference: −2.86% per kg/m2, P<0.01) were associated with declining serum testosterone. This association remained significant in sensitivity analysis, while in the stratified analysis, above association was not significant in men with diabetes or aged 65 and over.Conclusions: SUA levels might be negatively associated with serum testosterone in adult males.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exploration of the association between serum uric acid and testosterone in adult males: NHANES 2011–2016

Han¹,

Zhang²,

Cao³

et al. 2021

Transl Androl Urol

View full text Add to dashboard Cite

show abstract

“…Interestingly, compared with matched controls, male siblings of women with PCOS were found to have significantly elevated dehydroepiandrosterone-sulfate (DHEA-S) levels [ 9 , 10 , 14 ], as well as lower concentrations of bioavailable testosterone [ 5 ]. Recently, we have observed that exogenous testosterone potentiated lipid-lowering and extra-lipid effects of hypolipidemic agents in subjects with low testosterone levels [ 15 , 16 ]. Therefore, the aim of the current study was to compare the impact of atorvastatin on plasma levels of cardiometabolic risk factors between men whose sisters had either PCOS or were unaffected.…”

Section: Introductionmentioning

confidence: 99%

The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome

Krysiak

Szkróbka

2020

Pharmacol. Rep

Self Cite

View full text Add to dashboard Cite

Background Women with polycystic ovary syndrome (PCOS) are characterized by increased cardiometabolic risk. The aim of the current study was to compare the impact of atorvastatin on plasma levels of cardiometabolic risk factors between men whose sisters had either PCOS or were unaffected. Methods The study population consisted of two age-, fat-free mass index-, blood pressure- and plasma lipid-matched groups of men with elevated total and LDL cholesterol levels: 20 brothers of PCOS probands (group 1) and 20 brothers of healthy women (group 2). Both groups were then treated with atorvastatin (40 mg daily) for the following 6 months. At the beginning and at the end of the study, we assessed plasma lipid levels, glucose homeostasis markers and levels of dehydroepiandrosterone sulfate, testosterone, bioavailable testosterone, uric acid, high-sensitivity C-reactive protein (hsCRP), homocysteine, fibrinogen and 25-hydroxyvitamin D. Results At the beginning of the study, both treatment arms differed in the degree of insulin resistance, calculated bioavailable testosterone, as well as in plasma levels of dehydroepiandrosterone sulfate, uric acid, hsCRP and 25-hydroxyvitamin D. Although atorvastatin reduced total and LDL cholesterol levels, this effect was stronger in group 2 than group 1. In group 2, atorvastatin exerted also a more potent impact on hsCRP, fibrinogen and homocysteine. An unfavorable impact on insulin sensitivity was observed only in group 1; while, statistically significant changes in uric acid and 25-hydroxyvitamin D levels were found only in group 2. Conclusion The obtained results suggest that cardiometabolic effects of atorvastatin are less pronounced in male siblings of PCOS probands than in brothers of unaffected women.

show abstract

“…Furthermore, the effect of testosterone manipulation on the SUA levels has been inconsistently reported. Exogenous androgen injection significantly decreased the SUA levels in men with gout or with late-onset hypogonadism [8,9]. However, surgical or medical castration in prostate cancer patients led to a reduction in the SUA level in a small-scale or single-arm study [10,11].…”

Section: Discussionmentioning

confidence: 99%

Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study

Lee

Cho

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

ObjectivesAlthough estrogenic modulation of serum urate levels is well-known, the androgenic effect on urate homeostasis remains controversial. We investigated the effect of androgen deprivation therapy (ADT) on serum urate levels.MethodsWe retrospectively enrolled a total of 489 prostate cancer patients with available serum urate levels at baseline and 3 and 6 months after ADT (n = 150) or prostate surgery (n = 339). We extracted the demographic, clinical, and laboratory data from a data warehouse and compared the changes in urate levels between the two treatment groups and between the different ADT regimens (with versus without luteinizing hormone-releasing hormone (LHRH) agonists) using generalized estimating equation (GEE).ResultsThe baseline urate levels and the proportion of hyperuricemic subjects were comparable between the two groups. After 6 months, the urate levels were significantly decreased (by −0.66 mg/dL, 95% confidence interval (CI) [-0.81 to -0.51]) in the ADT group, whereas they did not significantly change in the surgery group in the univariate GEE analysis. The ADT group (4.7% from 18.0% at baseline) had a significantly lower proportion of hyperuricemic patients than surgery group (16.5% from 15.9% at baseline) at 6-month (p < 0.001). Regardless of whether LHRH agonists were used, the serial urate levels were lowered by the ADT. Temporal changes in the urate levels were significantly associated with the treatment group, baseline hyperuricemia, and poor functional or advanced cancer status. The ADT-related serum urate level reduction also remained significant in the multivariate GEE analysis (regression coefficient = −0.43 [−0.67 to −0.19] after 3 months and −0.37 [−0.64 to −0.10] after 6 months). Moreover, propensity-score-matched analyses yielded the same results.ConclusionsOur results showed that longitudinal serum urate levels were significantly reduced in men receiving ADT. This finding suggests that androgen could have an independent role in urate homeostasis.

show abstract

The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism

Abstract: Our study may suggest the clinical benefits associated with combination therapy with a statin and testosterone in elderly men with LOH.

Cited by 10 publications

References 36 publications

Exploration of the association between serum uric acid and testosterone in adult males: NHANES 2011–2016

Exploration of the association between serum uric acid and testosterone in adult males: NHANES 2011–2016

The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome

Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study

Contact Info

Product

Resources

About